Santarus Adds Two Drugs

Xconomy San Diego — 

Santarus, the San Diego-based drug developer, said today it has acquired two biotech drugs. Santarus (NASDAQ: SNTS) said it has acquired recombinant human C1 inhibitor (Rhucin) for hereditary angioedema from Netherlands-based Pharming Group for a $15 million upfront free and a $5 million milestone payment. Santarus is also getting a humanized anti-VLA1 antibody drug for inflammatory and autoimmune diseases via the acquisition of closely-held Covella Pharmaceuticals for $1.8 million. Last week, Santarus also sought to build up its pipeline by obtaining a drug candidate for type 2 diabetes.